SG11201806274SA - Copanlisib biomarkers - Google Patents
Copanlisib biomarkersInfo
- Publication number
- SG11201806274SA SG11201806274SA SG11201806274SA SG11201806274SA SG11201806274SA SG 11201806274S A SG11201806274S A SG 11201806274SA SG 11201806274S A SG11201806274S A SG 11201806274SA SG 11201806274S A SG11201806274S A SG 11201806274SA SG 11201806274S A SG11201806274S A SG 11201806274SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- biomarkers
- pct
- copanlisib
- english
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662289713P | 2016-02-01 | 2016-02-01 | |
US201662376017P | 2016-08-17 | 2016-08-17 | |
PCT/EP2017/051903 WO2017134000A1 (en) | 2016-02-01 | 2017-01-30 | Copanlisib biomarkers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806274SA true SG11201806274SA (en) | 2018-08-30 |
Family
ID=57984901
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806274SA SG11201806274SA (en) | 2016-02-01 | 2017-01-30 | Copanlisib biomarkers |
SG10202007262PA SG10202007262PA (en) | 2016-02-01 | 2017-01-30 | Copanlisib biomarkers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202007262PA SG10202007262PA (en) | 2016-02-01 | 2017-01-30 | Copanlisib biomarkers |
Country Status (16)
Country | Link |
---|---|
US (1) | US20190038632A1 (es) |
EP (1) | EP3411497A1 (es) |
JP (1) | JP2019511204A (es) |
KR (1) | KR20180101603A (es) |
CN (1) | CN108884496A (es) |
AU (1) | AU2017214230A1 (es) |
BR (1) | BR112018015782A2 (es) |
CA (1) | CA3012890A1 (es) |
CL (1) | CL2018002069A1 (es) |
MA (1) | MA43957A (es) |
MX (1) | MX2018009368A (es) |
PH (1) | PH12018501623A1 (es) |
SG (2) | SG11201806274SA (es) |
SV (1) | SV2018005730A (es) |
TN (1) | TN2018000271A1 (es) |
WO (1) | WO2017134000A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
CA2978830A1 (en) | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
US10844066B2 (en) | 2016-03-08 | 2020-11-24 | Bayer Pharma Aktiengesellschaft | 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
US10925880B2 (en) | 2016-09-23 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
WO2019002068A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST |
IL272857B2 (en) * | 2017-09-08 | 2024-03-01 | Bayer Consumer Care Ag | Cofanalisib formulations |
WO2020092860A1 (en) * | 2018-11-01 | 2020-05-07 | The Jackson Laboratory | Gastric cancer treatments |
EP4231872A1 (en) | 2020-10-21 | 2023-08-30 | Black Jet Innovations, Inc. | Mobile device grip and stand |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
UA122822C2 (uk) * | 2013-04-08 | 2021-01-06 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
AU2014282179B2 (en) * | 2013-06-20 | 2017-09-14 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic efficacy of PI3K/AKT/mTOR inhibitor on basis of PHLDA1 or PIK3C2B expression |
JP2017508469A (ja) * | 2014-03-11 | 2017-03-30 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 癌悪性度、予後及び治療に対する反応性の決定 |
WO2015160986A2 (en) * | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
CN105130997B (zh) * | 2015-09-25 | 2017-12-05 | 苏州明锐医药科技有限公司 | 一种库潘尼西的制备方法 |
-
2017
- 2017-01-30 CA CA3012890A patent/CA3012890A1/en not_active Abandoned
- 2017-01-30 MA MA043957A patent/MA43957A/fr unknown
- 2017-01-30 WO PCT/EP2017/051903 patent/WO2017134000A1/en active Application Filing
- 2017-01-30 SG SG11201806274SA patent/SG11201806274SA/en unknown
- 2017-01-30 AU AU2017214230A patent/AU2017214230A1/en not_active Abandoned
- 2017-01-30 BR BR112018015782A patent/BR112018015782A2/pt not_active IP Right Cessation
- 2017-01-30 EP EP17703683.7A patent/EP3411497A1/en not_active Withdrawn
- 2017-01-30 TN TNP/2018/000271A patent/TN2018000271A1/en unknown
- 2017-01-30 MX MX2018009368A patent/MX2018009368A/es unknown
- 2017-01-30 CN CN201780020013.7A patent/CN108884496A/zh active Pending
- 2017-01-30 SG SG10202007262PA patent/SG10202007262PA/en unknown
- 2017-01-30 JP JP2018539820A patent/JP2019511204A/ja active Pending
- 2017-01-30 US US16/074,728 patent/US20190038632A1/en not_active Abandoned
- 2017-01-30 KR KR1020187024847A patent/KR20180101603A/ko unknown
-
2018
- 2018-07-31 PH PH12018501623A patent/PH12018501623A1/en unknown
- 2018-08-01 CL CL2018002069A patent/CL2018002069A1/es unknown
- 2018-08-07 SV SV2018005730A patent/SV2018005730A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3411497A1 (en) | 2018-12-12 |
SV2018005730A (es) | 2018-12-05 |
SG10202007262PA (en) | 2020-09-29 |
CN108884496A (zh) | 2018-11-23 |
BR112018015782A2 (pt) | 2019-01-02 |
AU2017214230A1 (en) | 2018-08-09 |
CL2018002069A1 (es) | 2018-11-16 |
US20190038632A1 (en) | 2019-02-07 |
MA43957A (fr) | 2018-12-12 |
PH12018501623A1 (en) | 2019-06-03 |
CA3012890A1 (en) | 2017-08-10 |
JP2019511204A (ja) | 2019-04-25 |
WO2017134000A1 (en) | 2017-08-10 |
MX2018009368A (es) | 2018-09-05 |
KR20180101603A (ko) | 2018-09-12 |
TN2018000271A1 (en) | 2020-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806274SA (en) | Copanlisib biomarkers | |
SG11201806512VA (en) | Copanlisib biomarkers | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804934PA (en) | Novel Compounds | |
SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
SG11201804384UA (en) | Geometric configurations for gastric residence systems | |
SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201810177VA (en) | Pet-imaging immunomodulators | |
SG11201408383SA (en) | Methods of detecting diseases or conditions using circulating diseased cells | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201808539WA (en) | Mouth piece for cooling of oral tissue of a patient during chemotherapy treatment | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201810018TA (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
SG11201804916PA (en) | Three-dimensional polymer networks with channels situated therein | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201809341PA (en) | Mobile robot | |
SG11201805184TA (en) | Combination therapy | |
SG11201804889XA (en) | Fluid interface device for delivering fluid to and/or withdrawing fluid from a patient |